Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Biosimilars and Patient Safety
Under the Affordable Care Act, Congress authorized the FDA to create a new pathway for the approval of copies of next-generation biologic drugs that are already approved and on the market. These copies, called biosimilars, are near-reproductions of a biologic drug, and if manufactured safely they can expand access to life-saving, life-enhancing medicines. However, a small difference in manufacturing process or in the cell line can alter the molecular structure between an original product and its biosimilar copies. Even slight variations could result in serious health implications for patients. So, how would you feel about replacing your drugs with biosimilars?